Search Results - "Gleixner, Karoline V"

Successful treatment of vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT) by Thaler, Johannes, Ay, Cihan, Gleixner, Karoline V., Hauswirth, Alexander W., Cacioppo, Filippo, Grafeneder, Jürgen, Quehenberger, Peter, Pabinger, Ingrid, Knöbl, Paul

“…Cases of unusual thrombosis and thrombocytopenia after administration of the ChAdOx1 nCoV‐19 vaccine (AstraZeneca) have been reported. The term vaccine‐induced…”
Get full text

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches by Valent, Peter, Akin, Cem, Gleixner, Karoline V, Sperr, Wolfgang R, Reiter, Andreas, Arock, Michel, Triggiani, Massimo

“…Mastocytosis is a hematopoietic neoplasm defined by abnormal expansion and focal accumulation of clonal tissue mast cells in various organ-systems. The disease…”
Get full text

Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification by Trizuljak, Jakub, Sperr, Wolfgang R., Nekvindová, Lucie, Elberink, Hanneke O., Gleixner, Karoline V., Gorska, Aleksandra, Lange, Magdalena, Hartmann, Karin, Illerhaus, Anja, Bonifacio, Massimiliano, Perkins, Cecelia, Elena, Chiara, Malcovati, Luca, Fortina, Anna B., Shoumariyeh, Khalid, Jawhar, Mohamad, Zanotti, Roberta, Bonadonna, Patrizia, Caroppo, Francesca, Zink, Alexander, Triggiani, Massimo, Parente, Roberta, Bubnoff, Nikolas, Yavuz, Akif S., Hägglund, Hans, Mattsson, Mattias, Panse, Jens, Jäkel, Nadja, Kilbertus, Alex, Hermine, Olivier, Arock, Michel, Fuchs, David, Sabato, Vito, Brockow, Knut, Bretterklieber, Agnes, Niedoszytko, Marek, Anrooij, Björn, Reiter, Andreas, Gotlib, Jason, Kluin‐Nelemans, Hanneke C., Mayer, Jiri, Doubek, Michael, Valent, Peter

“…Background In indolent systemic mastocytosis (ISM), several risk factors of disease progression have been identified. Previous studies, performed with limited…”
Get full text

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML by Valent, Peter, Sadovnik, Irina, Eisenwort, Gregor, Bauer, Karin, Herrmann, Harald, Gleixner, Karoline V, Schulenburg, Axel, Rabitsch, Werner, Sperr, Wolfgang R, Wolf, Dominik

“…The concept of leukemic stem cells (LSC) has been developed with the idea to explain the clonal hierarchies and architectures in leukemia, and the more or less…”
Get full text

Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis by Greiner, Georg, Witzeneder, Nadine, Klein, Klara, Tangermann, Simone, Kodajova, Petra, Jaeger, Eva, Ratzinger, Franz, Gerner, Marlene C., Jawhar, Mohamad, Baumgartner, Sigrid, Fruehwirth, Karin, Schmetterer, Klaus G., Zuber, Johannes, Gleixner, Karoline V., Mayerhofer, Matthias, Schwarzinger, Ilse, Simonitsch-Klupp, Ingrid, Esterbauer, Harald, Baer, Constance, Walter, Wencke, Meggendorfer, Manja, Strassl, Robert, Haferlach, Torsten, Hartmann, Karin, Kenner, Lukas, Sperr, Wolfgang R., Reiter, Andreas, Sexl, Veronika, Arock, Michel, Valent, Peter, Hoermann, Gregor

“…•KIT D816V confers resistance to TNF via BIRC5 (survivin) and promotes clonal dominance.•High TNF levels are associated with inferior survival in SM. [Display…”
Get full text

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia by Warsch, Wolfgang, Kollmann, Karoline, Eckelhart, Eva, Fajmann, Sabine, Cerny-Reiterer, Sabine, Hölbl, Andrea, Gleixner, Karoline V., Dworzak, Michael, Mayerhofer, Matthias, Hoermann, Gregor, Herrmann, Harald, Sillaber, Christian, Egger, Gerda, Valent, Peter, Moriggl, Richard, Sexl, Veronika

“…In BCR-ABL1+ leukemia, drug resistance is often associated with up-regulation of BCR-ABL1 or multidrug transporters as well as BCR-ABL1 mutations. Here we show…”
Get full text

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts by Valent, Peter, Akin, Cem, Arock, Michel, Gleixner, Karoline V, Greinix, Hildegard, Hermine, Olivier, Horny, Hans-Peter, Ivanov, Daniel, Orfao, Alberto, Rabitsch, Werner, Reiter, Andreas, Schulenburg, Axel, Sotlar, Karl, Sperr, Wolfgang R, Ustun, Celalettin

“…Advanced systemic mastocytosis (SM) is a heterogeneous group of myeloid neoplasms characterized by an uncontrolled expansion of mast cells (MC) in one or more…”
Get full text

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis by Arock, Michel, Wedeh, Ghaith, Hoermann, Gregor, Bibi, Siham, Akin, Cem, Peter, Barbara, Gleixner, Karoline V, Hartmann, Karin, Butterfield, Joseph H, Metcalfe, Dean D, Valent, Peter

“…Mastocytosis is a term used to denote a group of rare diseases characterized by an abnormal accumulation of neoplastic mast cells in various tissues and…”
Get full text

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia by Gleixner, Karoline V, Schneeweiss, Mathias, Eisenwort, Gregor, Berger, Daniela, Herrmann, Harald, Blatt, Katharina, Greiner, Georg, Byrgazov, Konstantin, Hoermann, Gregor, Konopleva, Marina, Waliul, Islam, Cumaraswamy, Abbarna A, Gunning, Patrick T, Maeda, Hiroshi, Moriggl, Richard, Deininger, Michael, Lion, Thomas, Andreeff, Michael, Valent, Peter

“…In chronic myeloid leukemia, resistance against BCR-ABL1 tyrosine kinase inhibitors can develop because of mutations, activation of additional pro-oncogenic…”
Get full text

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis by Schneeweiss, Mathias, Peter, Barbara, Bibi, Siham, Eisenwort, Gregor, Smiljkovic, Dubravka, Blatt, Katharina, Jawhar, Mohamad, Berger, Daniela, Stefanzl, Gabriele, Herndlhofer, Susanne, Greiner, Georg, Hoermann, Gregor, Hadzijusufovic, Emir, Gleixner, Karoline V, Bettelheim, Peter, Geissler, Klaus, Sperr, Wolfgang R, Reiter, Andreas, Arock, Michel, Valent, Peter

“…Systemic mastocytosis is a complex disease defined by abnormal growth and accumulation of neoplastic mast cells in various organs. Most patients exhibit a…”
Get full text

Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study by Lucini, Chantal, Obrová, Klára, Krickl, Isabella, Nogueira, Filomena, Kocmanová, Iva, Herndlhofer, Susanne, Gleixner, Karoline V, Sperr, Wolfgang R, Frank, Tijana, Andrade, Nuno, Peters, Christina, Engstler, Gernot, Dworzak, Michael, Attarbaschi, Andishe, van Grotel, Martine, van den Heuvel-Eibrink, Marry M, Moiseev, Ivan S, Rogacheva, Yuliya, Zubarovskaya, Ludmilla, Zubarovskaya, Natalia, Pichler, Herbert, Lawitschka, Anita, Koller, Elisabeth, Keil, Felix, Mayer, Jiří, Weinbergerová, Barbora, Valent, Peter, Lion, Thomas

“…Invasive fungal disease (IFD) presents a life-threatening condition in immunocompromised patients, thus often prompting empirical administration of antifungal…”
Get full text

KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib by Gleixner, Karoline V., Mayerhofer, Matthias, Cerny-Reiterer, Sabine, Hörmann, Gregor, Rix, Uwe, Bennett, Keiryn L., Hadzijusufovic, Emir, Meyer, Renata A., Pickl, Winfried F., Gotlib, Jason, Horny, Hans-Peter, Reiter, Andreas, Mitterbauer-Hohendanner, Gerlinde, Superti-Furga, Giulio, Valent, Peter

“…Systemic mastocytosis (SM) either presents as a malignant neoplasm with short survival or as an indolent disease with normal life expectancy. In both…”
Get full text

Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal by Willmann, Michael, Yuzbasiyan-Gurkan, Vilma, Marconato, Laura, Dacasto, Mauro, Hadzijusufovic, Emir, Hermine, Olivier, Sadovnik, Irina, Gamperl, Susanne, Schneeweiss-Gleixner, Mathias, Gleixner, Karoline V, Böhm, Thomas, Peter, Barbara, Eisenwort, Gregor, Moriggl, Richard, Li, Zhixiong, Jawhar, Mohamad, Sotlar, Karl, Jensen-Jarolim, Erika, Sexl, Veronika, Horny, Hans-Peter, Galli, Stephen J, Arock, Michel, Vail, David M, Kiupel, Matti, Valent, Peter

“…Mast cell neoplasms are one of the most frequently diagnosed malignancies in dogs. The clinical picture, course, and prognosis vary substantially among…”
Get full text

Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis by Baumgartner, Christian, Cerny-Reiterer, Sabine, Sonneck, Karoline, Mayerhofer, Matthias, Gleixner, Karoline V, Fritz, Richard, Kerenyi, Marc, Boudot, Cedric, Gouilleux, Fabrice, Kornfeld, Jan-Wilhelm, Sillaber, Christian, Moriggl, Richard, Valent, Peter

“…Recent data suggest that the signal transducer and activator of transcription (STAT)5 contributes to differentiation and growth of mast cells. It has also been…”
Get full text

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells by Peter, Barbara, Cerny-Reiterer, Sabine, Hadzijusufovic, Emir, Schuch, Karina, Stefanzl, Gabriele, Eisenwort, Gregor, Gleixner, Karoline V, Hoermann, Gregor, Mayerhofer, Matthias, Kundi, Michael, Baumgartner, Sigrid, Sperr, Wolfgang R, Pickl, Winfried F, Willmann, Michael, Valent, Peter

“…Obatoclax exerts profound antineoplastic effects on malignant mast cells in advanced systemic mastocytosis, and shows synergistic growth‐inhibitory effects…”
Get full text

Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V by Gleixner, Karoline V, Peter, Barbara, Blatt, Katharina, Suppan, Verena, Reiter, Andreas, Radia, Deepti, Hadzijusufovic, Emir, Valent, Peter

“…Patients with advanced systemic mastocytosis, including mast cell leukemia, have a poor prognosis. In these patients, neoplastic mast cells usually harbor the…”
Get full text

CD34+/CD38− stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin by HERRMANN, Harald, CERNY-REITERER, Sabine, SCHWARZINGER, Ilse, SPERR, Wolfgang R, VALENT, Peter, GLEIXNER, Karoline V, BLATT, Katharina, HERNDLHOFER, Susanne, RABITSCH, Werner, JÄGER, Eva, MITTERBAUER-HOHENDANNER, Gerlinde, STREUBEL, Berthold, SELZER, Edgar

“…CD33 is a well-known stem cell target in acute myeloid leukemia. So far, however, little is known about expression of CD33 on leukemic stem cells in chronic…”
Get full text

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs by Aichberger, Karl J., Gleixner, Karoline V., Mirkina, Irina, Cerny-Reiterer, Sabine, Peter, Barbara, Ferenc, Veronika, Kneidinger, Michael, Baumgartner, Christian, Mayerhofer, Matthias, Gruze, Alexander, Pickl, Winfried F., Sillaber, Christian, Valent, Peter

“…Systemic mastocytosis (SM) is a myeloid neoplasm involving mast cells (MCs) and their progenitors. In most cases, neoplastic cells display the D816V-mutated…”
Get full text

Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib by Mayerhofer, Matthias, Gleixner, Karoline V., Mayerhofer, Julia, Hoermann, Gregor, Jaeger, Eva, Aichberger, Karl J., Ott, Rene G., Greish, Khaled, Nakamura, Hideaki, Derdak, Sophia, Samorapoompichit, Puchit, Pickl, Winfried F., Sexl, Veronika, Esterbauer, Harald, Schwarzinger, Ilse, Sillaber, Christian, Maeda, Hiroshi, Valent, Peter

“…Resistance toward imatinib and other BCR/ABL tyrosine kinase inhibitors remains an increasing clinical problem in the treatment of advanced stages of chronic…”
Get full text

The effects of dasatinib on IgE receptor–dependent activation and histamine release in human basophils by Kneidinger, Michael, Schmidt, Uwe, Rix, Uwe, Gleixner, Karoline V., Vales, Anja, Baumgartner, Christian, Lupinek, Christian, Weghofer, Margit, Bennett, Keiryn L., Herrmann, Harald, Schebesta, Alexandra, Thomas, Wayne R., Vrtala, Susanne, Valenta, Rudolf, Lee, Francis Y., Ellmeier, Wilfried, Superti-Furga, Giulio, Valent, Peter

“…Dasatinib is a multitargeted drug that blocks several tyrosine kinases. Apart from its well-known antileukemic activity, the drug has attracted attention…”
Get full text